Kyverna Therapeutics, Inc. (KYTX) vs ARS Pharmaceuticals, Inc. (SPRY)
Kyverna Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are both Biotechnology companies. Kyverna Therapeutics, Inc. and ARS Pharmaceuticals, Inc. are of similar size ($432.3M and $412.7M). Kyverna Therapeutics, Inc. has the higher net margin (0.00% vs −184.3%) and the higher return on invested capital (0.00% vs −335.7%). Across the 13 metrics below, Kyverna Therapeutics, Inc. leads on 12 and ARS Pharmaceuticals, Inc. on 1.
Valuation
Profitability
| Metric | KYTX | SPRY | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 71.37% | 65.16% |
| Operating margin | 0.00% | (184.96%) | 0.00% |
| Net margin | 0.00% | (184.26%) | 0.00% |
| Free cash flow margin | 0.00% | (167.97%) | 0.00% |
| Return on equity | (87.24%) | (210.37%) | (57.72%) |
| Return on assets | (68.40%) | (76.54%) | (49.22%) |
| Return on invested capital | 0.00% | (335.65%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack